ENTRADA THERAPEUTICS, INC. Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities
ENTRADA THERAPEUTICS, INC. (TRDA) reported Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities of -$4.68 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities · last filed 2026-08-05
- ENTRADA THERAPEUTICS, INC. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2026-06-30 was $1.27M, a 70.49% decline year-over-year.
- ENTRADA THERAPEUTICS, INC. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2026-03-31 was -$5.95M.
- ENTRADA THERAPEUTICS, INC. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2025-12-31 was $2.15M.
- ENTRADA THERAPEUTICS, INC. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2025-09-30 was $3.74M, a 22.97% increase year-over-year.
- ENTRADA THERAPEUTICS, INC. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2025 was $4.74M, a 177.63% increase from fiscal 2024.
- ENTRADA THERAPEUTICS, INC. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2024 was $1.71M, a 55.19% decline from fiscal 2023.
- ENTRADA THERAPEUTICS, INC. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2023 was $3.81M, a 116.35% increase from fiscal 2022.
- ENTRADA THERAPEUTICS, INC. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2022 was $1.76M, a 55.53% decline from fiscal 2021.
| Period end | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 3 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 6 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 9 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.27M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$4.68M 10-Q · filed 2026-08-05 | -$2.53M derived: sum of 3 quarters · filed 2026-08-05 | $1.21M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | -$5.95M 10-Q · filed 2026-05-07 | -$3.80M derived: sum of 2 quarters · filed 2026-05-07 | -$65.00K derived: sum of 3 quarters · filed 2026-05-07 | $4.25M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $2.15M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $5.89M derived: sum of 2 quarters · filed 2026-02-26 | $10.20M derived: sum of 3 quarters · filed 2026-08-05 | $4.74M 10-K · filed 2026-02-26 |
| 2025-09-30 | $3.74M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $8.05M derived: sum of 2 quarters · filed 2026-08-05 | $2.59M 10-Q · filed 2025-11-06 | $2.17M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $4.31M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$1.15M 10-Q · filed 2026-08-05 | -$1.57M derived: sum of 3 quarters · filed 2026-08-05 | $1.47M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | -$5.46M 10-Q · filed 2026-05-07 | -$5.88M derived: sum of 2 quarters · filed 2026-05-07 | -$2.85M derived: sum of 3 quarters · filed 2026-05-07 | -$1.23M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$425.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $2.61M derived: sum of 2 quarters · filed 2026-02-26 | $4.23M derived: sum of 3 quarters · filed 2026-02-26 | $1.71M 10-K · filed 2026-02-26 |
| 2024-09-30 | $3.04M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $4.66M derived: sum of 2 quarters · filed 2025-11-06 | $2.13M 10-Q · filed 2025-11-06 | $4.09M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $1.62M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | -$906.00K 10-Q · filed 2025-08-06 | $1.05M derived: sum of 3 quarters · filed 2025-08-06 | $3.85M derived: sum of 4 quarters · filed 2025-08-06 |
| 2024-03-31 | -$2.52M 10-Q · filed 2025-05-08 | -$567.00K derived: sum of 2 quarters · filed 2025-05-08 | $2.23M derived: sum of 3 quarters · filed 2025-05-08 | -$2.82M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $1.96M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $4.75M derived: sum of 2 quarters · filed 2025-02-27 | -$295.00K derived: sum of 3 quarters · filed 2025-02-27 | $3.81M 10-K · filed 2025-02-27 |
| 2023-09-30 | $2.80M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-05 | -$2.25M derived: sum of 2 quarters · filed 2024-11-05 | $1.86M 10-Q · filed 2024-11-05 | -$2.48M derived: sum of 4 quarters · filed 2024-11-05 |
| 2023-06-30 | -$5.05M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | -$943.00K 10-Q · filed 2024-08-13 | -$5.29M derived: sum of 3 quarters · filed 2024-08-13 | $1.62M derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | $4.11M 10-Q · filed 2024-05-07 | -$235.00K derived: sum of 2 quarters · filed 2024-05-07 | $6.67M derived: sum of 3 quarters · filed 2024-05-07 | $7.39M derived: sum of 4 quarters · filed 2024-05-07 |
| 2022-12-31 | -$4.34M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-13 | $2.56M derived: sum of 2 quarters · filed 2024-03-13 | $3.29M derived: sum of 3 quarters · filed 2024-03-13 | $1.76M 10-K · filed 2024-03-13 |
| 2022-09-30 | $6.90M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $7.63M derived: sum of 2 quarters · filed 2023-11-07 | $6.10M 10-Q · filed 2023-11-07 | $7.93M derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | $726.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | -$800.00K 10-Q · filed 2023-08-08 | $1.02M derived: sum of 3 quarters · filed 2023-08-08 | $3.09M derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | -$1.53M 10-Q · filed 2023-05-10 | $298.00K derived: sum of 2 quarters · filed 2023-05-10 | $2.36M derived: sum of 3 quarters · filed 2023-05-10 | $2.95M derived: sum of 4 quarters · filed 2023-05-10 |
| 2021-12-31 | $1.82M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-06 | $3.89M derived: sum of 2 quarters · filed 2023-03-06 | $4.47M derived: sum of 3 quarters · filed 2023-03-06 | $3.96M 10-K · filed 2023-03-06 |
| 2021-09-30 | $2.06M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07 | $2.65M derived: sum of 2 quarters · filed 2022-11-07 | $2.14M 10-Q · filed 2022-11-07 | $2.50M derived: sum of 4 quarters · filed 2022-11-07 |
| 2021-06-30 | $583.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $73.00K 10-Q · filed 2022-08-11 | $430.00K derived: sum of 3 quarters · filed 2022-08-11 | |
| 2021-03-31 | -$510.00K 10-Q · filed 2022-05-12 | -$153.00K derived: sum of 2 quarters · filed 2022-05-12 | ||
| 2020-12-31 | $357.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-15 | $578.00K 10-K · filed 2022-03-15 | ||
| 2020-09-30 | $221.00K 10-Q · filed 2021-12-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |